LNSR vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LNSR exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -2.63, indicating negative shareholder equity. The company is suffering from catastrophic profitability metrics, including an ROE of -1069.41% and an operating margin of -116.03%. Despite a 'strong_buy' analyst consensus from a very small sample (2 analysts), the fundamental data shows declining revenue (-4.20% YoY) and a consistent failure to meet earnings estimates (0/4 beats in the last year). The technical trend is aggressively bearish, with a 51.6% price collapse in the last month alone.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
LNSR vs MRK: Head-to-Head Comparison
This page compares LENSAR, Inc. (LNSR) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.